Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs.
Business Model:
Revenue: $0
Employees: 1-10
Address:
City: Dijon
State: Bourgogne
Zip:
Country: France
Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies. Exeliom develops a new class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system. The company was founded in 2016 and is headquartered in Dijon, France.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2023 | Series A | 5 | $8.7M |
Auriga Partners Biocodex Capital Grand Est CE-Ventures UI Investissement Auriga Partners Biocodex Capital Grand Est CE-Ventures UI Investissement Auriga Partners Biocodex Capital Grand Est CE-Ventures UI Investissement |
7/2018 | Series A | 5 | $8.2M |
Auriga Partners Biocodex Cap Innov&s;Est INRA Sofimac Innovation Auriga Partners Biocodex Cap Innov&s;Est INRA Sofimac Innovation |
1/2021 | Series A | $3.6M | 8/2020 | Grant | 1 | $2.9M |
European Innovation Council European Innovation Council European Innovation Council |
8/2019 | Grant | 1 | $2M |
Bpifrance Bpifrance Bpifrance |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|